BenchSci is an AI-driven biotechnology company that empowers scientists to run more successful experiments and accelerate drug discovery. Their platform, ASCEND™, uses machine learning to decode and connect experimental data from scientific literature, proprietary customer data, and public datasets. This enables researchers to make more informed decisions, identify optimal reagents, uncover biological connections, and design better experiments. BenchSci aims to reduce the high failure rates in preclinical research, ultimately helping to bring novel medicines to patients faster by improving R&D productivity.
Serves as the central hub for BenchSci's global operations, including research and development of its AI platform, product management, engineering, data science, sales, marketing, and corporate functions.
Modern office space designed to foster collaboration and innovation, featuring open-plan areas, dedicated project rooms, and advanced technological infrastructure. Its location offers direct access to a rich talent pool and key partners.
BenchSci promotes a mission-driven, collaborative, and learning-oriented work environment. It emphasizes innovation, tackling complex scientific and technological challenges, and values diversity, inclusion, and a strong sense of purpose in impacting global health.
The Toronto headquarters is pivotal due to its location in a major AI and biotech ecosystem, providing access to top talent, research collaborations, and a supportive innovation network. It is the core of BenchSci's technological development and global strategy.
BenchSci serves a global clientele of pharmaceutical companies, contract research organizations (CROs), and academic institutions. While its primary R&D and operational hub is in Toronto, Canada, it has established a significant presence in key international biotech ecosystems, including Boston, USA, and Cambridge, UK, to provide localized support and strategic engagement. Its AI-powered platform, ASCEND™, is utilized by scientists worldwide, enabling remote access and data-driven decision-making for preclinical research across diverse geographical regions.
250 University Ave, Suite 500
Toronto
Ontario
Canada
Address: Presence in Boston's biotech hub; specific large office address not publicly emphasized, likely leveraging flexible/hybrid models.
To engage directly with leading pharmaceutical companies, biotech firms, and academic research institutions in one of the world's largest life sciences clusters, fostering collaborations and customer relationships.
Address: Operations centered around The Bradfield Centre, Cambridge Science Park, a key innovation hub.
To expand BenchSci's footprint in Europe, providing localized support and building strategic partnerships in another critical global life sciences innovation center, enhancing service to European clients.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, BenchSci' leadership includes:
BenchSci has been backed by several prominent investors over the years, including:
BenchSci has strategically strengthened its executive leadership over the past 12 months with key appointments, including a new President and CFO, to spearhead its continued growth, market expansion, and innovation in AI-driven drug discovery.
Discover the tools BenchSci uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
BenchSci commonly uses the [first].[last]@benchsci.com email format for its employees. While other formats might exist within the organization, this is the most widely observed pattern.
[first].[last]@benchsci.com
Format
jane.doe@benchsci.com
Example
85%
Success rate
PR Newswire • May 7, 2024
BenchSci announced the appointment of Lilli Zakarija as its new President. Zakarija will lead BenchSci's global go-to-market functions, including sales, marketing, customer success, and strategic partnerships, to drive the company's next phase of growth and scale its operations....more
Business Wire • November 15, 2023
BenchSci secured USD 50 million in Series D funding led by Generation Investment Management, with participation from existing investors. The capital will be used to expand its AI drug discovery platform, ASCEND™, aimed at improving R&D productivity by transforming how scientists conduct preclinical research....more
PR Newswire • July 12, 2023
BenchSci announced that Casper Wong joined the company as Chief Financial Officer. Wong brings over 20 years of experience in finance and operations at high-growth technology companies and will oversee BenchSci's financial strategy and operations as it continues to scale....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including BenchSci, are just a search away.